Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NACompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
ObesityFertility
Interventions
DRUG

Degarelix (GnRH antagonist)

Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.

DRUG

recombinant FSH

Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.

DRUG

Cetrorelix

Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.

Trial Locations (1)

80045

University of Colorado Clinical and Translational Research Center, Aurora

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of Colorado, Denver

OTHER

NCT02478775 - Dysregulation of FSH in Obesity: Functional and Statistical Analysis | Biotech Hunter | Biotech Hunter